Provectus Biopharmaceuticals, Inc. (PVCT)
USD 0.13
(-0.76%)
USD 0.13
(-0.76%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -2.57 Million | -3.04 Million | -1.01 Million | -4.08 Million | -6.19 Million | -5.2 Million |
| Net Income | -3.1 Million | -3.55 Million | -5.53 Million | -6.67 Million | -6.92 Million | -8.15 Million |
| Depreciation & Amortization | 8921.00 | 10.89 Thousand | 12.86 Thousand | 241.79 Thousand | 685.21 Thousand | 685.21 Thousand |
| Deferred income taxes | -439.14 Thousand | - | -63.09 Thousand | - | - | - |
| Stock-based compensation | 2850.00 | 3025.00 | 23.68 Thousand | 134.75 Thousand | 22.97 Thousand | 80 Thousand |
| Change in working capital | 472.92 Thousand | 446.4 Thousand | 4.47 Million | 2.14 Million | -47.01 Thousand | 2.18 Million |
| Other non-cash items | 484.24 Thousand | 52.88 Thousand | 81.25 Thousand | 73.57 Thousand | 71.15 Thousand | 80 Thousand |
| Investing Cash Flow | - | - | - | - | - | - |
| Investments in PPE | -2.00 | - | - | - | - | - |
| Acquisitions | - | - | - | - | - | - |
| Investment purchases | - | - | - | - | - | - |
| Sales/Maturities of investments | - | - | - | - | - | - |
| Other Investing Activities | - | - | - | - | - | - |
| Financing Cash Flow | 2.19 Million | 1.36 Million | 4.02 Million | 3.6 Million | 6.75 Million | 5.15 Million |
| Debt repayment | -2.19 Million | -259.65 Thousand | -248.17 Thousand | -105.98 Thousand | -6.41 Million | -4.47 Million |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | - | - | 962.22 Thousand | 418.67 Thousand | 268.94 Thousand | 80 Thousand |
| Other Financing Activities | -5.00 | 1.62 Million | 3.31 Million | 3.28 Million | 12.89 Million | 5.07 Million |
| Accounts receivables | -82.00 | 4481.00 | -1449.00 | 50.32 Thousand | 4907.00 | 528.23 Thousand |
| Accounts payables | -418.37 Thousand | 807.07 Thousand | 331.14 Thousand | -170.41 Thousand | -2.18 Million | 41.54 Thousand |
| Inventory | - | -4481.00 | 1449.00 | -50.32 Thousand | -4907.00 | - |
| Other working capital | 891.37 Thousand | -360.66 Thousand | 4.14 Million | 2.31 Million | 2.13 Million | 2.14 Million |
| Cash at beginning of period | 1.43 Million | 3.1 Million | 97.23 Thousand | 590.7 Thousand | 50.98 Thousand | 105.5 Thousand |
| Cash at end of period | 1.02 Million | 1.43 Million | 3.1 Million | 97.23 Thousand | 590.7 Thousand | 50.98 Thousand |
| Capital Expenditure | -2.00 | - | - | - | - | - |
| Effect of forex changes on cash | -24.48 Thousand | -1604.00 | -1031.00 | -7871.00 | -24 Thousand | - |
| Net cash flow / Change in cash | -404.9 Thousand | -1.67 Million | 3 Million | -493.47 Thousand | 539.72 Thousand | -54.51 Thousand |
| Free Cash Flow | -2.57 Million | -3.04 Million | -1.01 Million | -4.08 Million | -6.19 Million | -5.2 Million |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 FY | 2023 Q4 | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | -846.84 Thousand | -504.04 Thousand | -3.1 Million | -663.41 Thousand | -775.83 Thousand | -835.06 Thousand |
| Depreciation & Amortization | 2230.00 | 2231.00 | 8921.00 | 2230.00 | 2230.00 | 2231.00 |
| Deferred income taxes | - | - | -439.14 Thousand | - | - | - |
| Stock-based compensation | - | - | 2850.00 | 2850.00 | - | - |
| Change in working capital | 70.25 Thousand | -554.31 Thousand | 472.92 Thousand | 88.48 Thousand | -9456.00 | 203.84 Thousand |
| Other non-cash items | 64.92 Thousand | 321.46 Thousand | 484.24 Thousand | 11.48 Thousand | 14.19 Thousand | 11.2 Thousand |
| Investing Cash Flow | - | - | - | 49.99 Thousand | -49.99 Thousand | - |
| Investments in PPE | 5.00 | - | - | - | - | - |
| Acquisitions | - | - | - | - | - | - |
| Investment purchases | - | - | - | - | - | - |
| Sales/Maturities of investments | - | - | - | - | - | - |
| Other Investing Activities | - | - | - | 49.99 Thousand | - | - |
| Financing Cash Flow | 588.95 Thousand | 781.09 Thousand | 2.19 Million | 201.55 Thousand | 817.85 Thousand | 656.44 Thousand |
| Debt repayment | -588.95 Thousand | -781.09 Thousand | -2.19 Million | -201.55 Thousand | -82.14 Thousand | -68.55 Thousand |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | - | - | - | - | - | - |
| Other Financing Activities | 588.95 Thousand | 781.09 Thousand | -5.00 | 201.55 Thousand | 900 Thousand | 725 Thousand |
| Accounts receivables | -664.00 | 365.00 | -82.00 | 471.00 | 813.00 | -973.00 |
| Accounts payables | -48.02 Thousand | -305.73 Thousand | -418.37 Thousand | -109.64 Thousand | -204.02 Thousand | 81.57 Thousand |
| Inventory | - | - | - | -553.00 | -813.00 | 973.00 |
| Other working capital | 118.95 Thousand | -248.94 Thousand | 891.37 Thousand | 197.65 Thousand | 194.56 Thousand | 122.26 Thousand |
| Cash at beginning of period | 762.75 Thousand | 1.02 Million | 1.43 Million | 1.41 Million | 1.35 Million | 1.32 Million |
| Cash at end of period | 589.28 Thousand | 762.75 Thousand | 1.02 Million | 1.02 Million | 1.41 Million | 1.35 Million |
| Capital Expenditure | 5.00 | - | - | - | - | - |
| Effect of forex changes on cash | 164.00 | -647.00 | -24.48 Thousand | -23.74 Thousand | 2063.00 | -954.00 |
| Net cash flow / Change in cash | -173.46 Thousand | -264.04 Thousand | -404.9 Thousand | -383.4 Thousand | 51.04 Thousand | 37.7 Thousand |
| Free Cash Flow | -762.58 Thousand | -1.04 Million | -2.57 Million | -561.21 Thousand | -768.87 Thousand | -617.78 Thousand |
BIOVIC-B
EDRWY
GBK
BEWFF
8433
PLT